



QT IMAGING

NASDAQ:QTI

Quantitative Transmission Imaging

Breast Acoustic CT™ Scanner

May 2026



Disclaimer

ABOUT THIS PRESENTATION

This investor presentation (this "Presentation") is provided for informational purposes only. The information contained herein does not purport to be all-inclusive and neither QT Imaging Holdings, Inc. (the "Company", "QT Imaging Holdings", "QTI"), nor its respective directors, officers, employees, agents, advisors or affiliates, including QT Imaging, Inc. ("QT Imaging"), makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation, which has not been verified and is subject to change at any time. Viewers of this Presentation should each make their own evaluation of QT Imaging Holdings and of the relevance and accuracy of the information and should make such other investigations as they deem necessary. To the fullest extent permitted by law, no responsibility or liability whatsoever is accepted by QT Imaging Holdings, or its directors, officers, employees, agents, advisors or affiliates for any loss howsoever arising, directly or indirectly, from any use of this Presentation or such information or opinions contained herein or otherwise arising in connection herewith.

This Presentation does not constitute (i) a solicitation of a proxy, consent or authorization with respect to any securities or (ii) an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of QT Imaging Holdings, or any of its affiliates, nor shall there be any sale, issuance or transfer of securities in any jurisdiction where, or to any person to whom, such offer, solicitation or sale would be unlawful. You should not construe the contents of this Presentation as legal, tax, accounting or investment advice or a recommendation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this Presentation, you confirm that you are not relying upon the information contained herein to make any decision.

On June 6, 2017, the U.S. Food and Drug Administration ("FDA") in response to QT Imaging's Section 510(k) Summary of Safety and Effectiveness premarket notification under the Food, Drug and Cosmetic Act, determined that the QT Breast Scanner is substantially equivalent to the predicate device. Our use of the words "safe", "safety", "effectiveness", and "efficacy" in relation to the QT Breast Scanner in this Presentation and all other QT Imaging related documents is limited to the context of the Section 510(k) Summary of Safety and Effectiveness that was reviewed and responded to by the FDA.

TRADEMARKS AND INTELLECTUAL PROPERTY

All trademarks, service marks, and trade names of QT Imaging Holdings or its affiliates used herein are trademarks, service marks, or registered trade names of QT Imaging Holdings or its affiliates, as noted herein. Any other product, company names, or logos mentioned herein are the trademarks and/or intellectual property of their respective owners, and their use is not intended to, and does not imply, a relationship with QT Imaging Holdings or its affiliates, or an endorsement or sponsorship by or of QT Imaging Holdings or its affiliates. Solely for convenience, the trademarks, service marks and trade names referred to in this presentation may appear without the ®, TM or SM symbols, but such references are not intended to indicate, in any way, that QT Imaging Holdings or its affiliates will not assert, to the fullest extent under applicable law, their rights or the right of the applicable licensor to these trademarks, service marks and trade names.

NON-GAAP FINANCIAL MEASURES

This presentation includes references to EBITDA and Adjusted EBITDA, financial measures that have not been prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). EBITDA is defined as loss before interest expense, income tax expense, depreciation and amortization. Adjusted EBITDA is defined as EBITDA further adjusted for stock-based compensation, net change in fair value of the derivative, earnout and warrant liabilities, transaction expenses, warrant modification expense, loss on debt extinguishment, debt issuance expense and other income (expense), net. Similar excluded expenses may be incurred in future periods when calculating these measures. QT Imaging believes these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. QT Imaging believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating projected operating results and trends and in comparing QT Imaging's financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. Certain of the financial metrics in this presentation can be found in QT Imaging's Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 18, 2026, and the reconciliation of EBITDA and Adjusted EBITDA can be found on pages 72 and 73 of this presentation.

Disclaimer

FORWARD LOOKING STATEMENTS

Certain statements included in this Presentation that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “has the potential to”, “believe”, “may”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “should”, “would”, “plan”, “predict”, “potential”, “seem”, “seek”, “future”, “outlook”, and similar expressions that indicate or predict future events or trends that are not statements of historical matters. These forward looking statements include, but are not limited to, the potential impact on existing medical technology, the company’s technology, including, the evolution of the Company into a scalable imaging platform combining proprietary hardware, advanced image reconstruction software, and AI-powered clinical decision tools to address the growing need for precision in breast health and the performance of software enhancements, product offerings, including QTI Cloud Platform and SaaS pricing model, business prospects, revenue, client adoptions, commercialization, including in Saudi Arabia and UAE, timing of reimbursement codes, projections of market opportunity, regulatory approvals and statements regarding estimates and forecasts of other financial and performance metrics. These statements are based on various assumptions, whether or not identified in this Presentation, and on the current expectations of QT Imaging Holdings’ management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not circumstances intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. In addition, statements regarding the Company’s products, technology, and market opportunity reflect the beliefs and opinions of QT Imaging Holdings’ management on the relevant subject as of this Presentation. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of QT Imaging Holdings. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; risks related to the rollout of QT Imaging Holdings’ business and the timing of expected business milestones; the demand for QT Imaging Holdings’ products and services; the ability of QT Imaging Holdings to increase sales of its output products in accordance with its plans; issues that could arise with respect to the manufacture of QT scanners by CMSC; the desire of customers and service recipients to continue engaging QT Imaging Holdings; the effects of competition on QT Imaging Holdings’ future business, changes in the Company’s strategy, future operations, financial positions, and product development timeline. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that QT Imaging Holdings presently does not know or believes is immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect QT Imaging Holdings’ expectations, plans or forecasts of future events and views as of the date of this Presentation. QT Imaging Holdings anticipates that subsequent events and developments will cause its assessments to change. However, while QT Imaging Holdings may elect to update these forward-looking statements at some point in the future, its specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing QT Imaging Holdings’ assessments as of any date subsequent to the date of this Presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements.

RISK FACTORS

An investment in our common stock involves a high degree of risk. The risk factors described below are not intended to be exhaustive and are not the only risks facing us. Additional risks not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and cash flows in future periods or are not identified because they are generally common to businesses. The occurrence of one or more of the events or circumstances described in these risk factors, along or in combination with other events or circumstances, could harm our business, financial condition, results of operations, and growth prospects. In such event, the market price of our common stock could decline, and you may lose all or part of your investment. The following should be read in conjunction with the respective consolidated financial statements of the Company, and the notes to the consolidated financial statements included therein. Risk factors include, but are not limited to:

- We are a development-stage company with limited operating history and significant losses since inception which may make it difficult to evaluate prospects for our future viability and predict our future performance. We may never be able to effectuate our business plan or achieve any meaningful revenue or reach profitability.
- We may not be able to successfully execute our business model.
- We have a limited operating history. If we successfully commercially launch the QTI Breast Acoustic CT Scanner, as well as products under development that are cleared by the FDA and other regulatory agencies, and they do not achieve widespread market acceptance, we will not be able to generate the revenue necessary to support our business.
- We may need to raise additional capital, which may not be available on favorable terms, if at all, and which may cause dilution to stockholders, restrict our operations or adversely affect our ability to operate our business.
- Our ability to generate the amount of cash needed to pay interest and principal on any indebtedness and our ability to refinance all or a portion of our indebtedness or obtain additional financing depends on many factors beyond our control.
- Our debt agreements contain restrictions that may limit our flexibility in operating our business.
- We are highly dependent on the successful development, marketing and sale of our breast imaging device and on other products and product candidates which are still in the development stage.

Our Mission

Transforming Breast Health For Every Woman



At QT Imaging, we are redefining what's possible in breast imaging - **delivering safe, high-resolution, and cost-effective solutions where traditional technologies fall short.** Our goal is to replace outdated breast imaging workflows with the first scalable 3D safe imaging platform for **dense breast diagnostics and precision breast oncology.**

QT Imaging Transformation



\$18M from NIH to develop supplemental imaging modality to resolve dense breasts

2012-2025



QTI becomes public on NASDAQ

Mar 2024

\$18 Million

Raise \$18M PIPE

Oct 2025



Approval of Reimbursement Category III CPT Code

Feb 2026

2012

Company founded by John Klock, MD

2017

FDA Clearance



Feb 2025

QTI gets delisted, public on OTC, QTIH

OTC Markets

Jan 2026

Relisted on Nasdaq



The Pain and Why QT Imaging



The Pain

- Mammography misses cancers in dense breasts / it is painful.
- MRI is expensive / slow / uncomfortable / contrast injection
- Ultrasound is operator dependent
- Workflow is fragmented
- High anxiety / recall / attrition



Why QT Imaging

- QT Imaging has uniquely differentiated solution
- Accurate diagnosis in dense breasts
- Product is validated and FDA cleared
- Commercial engine is now live
- Reimbursement de-risks adoption
- Financial inflection is imminent
- AI / biomarkers provide upside

Accurate Imaging for Dense Breasts

Today's Challenge:

Multi-step, patient anxiety and attrition prone process with high number of unnecessary biopsies

QT Imaging Solution:

Single step (Supplemental + Dx) patient friendly process, with potential to reduce unnecessary biopsies

Primary Screening



Breast Density Confirmation

Supplemental Screening



Diagnostic Imaging



Biopsy via HHUS or MRI



QT Imaging provides **no radiation, no contrast, no compression** imaging with **no operator variability** that requires less scheduling leading to **less patient anxiety** and attrition.

QT Imaging Value Proposition

For the Patient



- One-stop-shop supplemental + diagnostic imaging
- No radiation, no compression, no contrast
- Low recall, less anxiety
- Operator independent

For the Clinician



- One test – multiple results (MRI like Imaging)
- Calcium visualization (DCIS + Ca, Density, Doubling, Cyst/Solid, Implant)
- Biomarkers: reflection, speed of sound, attenuation & breast density measure (FGR)
- Low recall, operator independence
- Potential to reduce unnecessary biopsies

For the Administrator




- 2.5 X more revenue per scan compared to mammography + handheld ultrasound
- 30% less annual labor cost – nonspecialized personnel
- Comparable siting costs and annual service
- Reduced overhead with one-stop-shop
- **3-year investment recovery with 5 patients/day**

This is one of the rare cases where patients, doctors, and providers all win.

Our Technology and Product


- **FDA-cleared**, patent protected breast imaging modality
- **Pain free, safe, no radiation or contrast**
- Inherently 3D quantitative, imaging modality, thus it's **high resolution, similar to MRI**
- Two independent sources of information:
 - CT-like configuration with ultrasound to acquire and reconstruct **transmission images** – unique biomarker, speed of sound
 - **Reflection images** for high-resolution depiction of tissue interfaces, as well as improved lesion visualization (cancers have irregular, heterogeneous reflective signatures)
- Overcomes **operator dependence and lack of standardization** associated with HHUS



QT Imaging's proprietary imaging technology delivers MRI like diagnostic performance in a safer, more scalable, and more patient friendly platform.

Optimized Patient Experience

- **No ionizing radiation.** Acoustic source only
- **No breast compression** and associated discomfort
- 10-12 minutes per breast exam time
- Quiet and comfortable (compared to MRI – claustrophobia, coil pressure, noise, lengthy exams)
- **No contrast injection or associated risk** (compared to MRI Gadolinium)
- **No limitations for dense breasts or implants**



Quantitative Imaging Platform Enables AI and Biomarker Expansion



Biomarker Development

- Unique quantitative data: Speed of Sound, Attenuation, Reflection, Nakagami parameters etc.
- Early detection of malignancy using defined quantitative thresholds
- Therapy monitoring such as pathological complete response (pCR) prediction in neoadjuvant therapy
- Personalized medicine, by correlating imaging biomarkers with genomic and histopathologic data
- Automated lesion characterization and BI-RADS aligned standardization for consistent interpretation

Cloud-Based AI Integration

- Deployment within QTI Cloud SaaS Integration via InteleShare's framework
- Automated pipelines for image reconstruction, feature extraction, Probability of Cancer Map generation
- Continuous learning from clinical data uploads and feedback loops



QT IMAGING

Our Market,
Why Now, and
How It Fits In



QT Imaging's Technology Has the Opportunity to Transform the Breast Imaging Market

CURRENT MARKET

**Breast Imaging:
\$6B MARKET ⁽¹⁾**

- FDA approved as supplemental screening device for breast imaging
- Aim to revolutionize current imaging paradigm, replacing mammography + ultrasound (handheld and automated), and freeing MRI scanners time



Layer

Description

**2025
Value**

**2030
Value**

CAGR

TAM

Total global opportunity (dense-breast supplemental screening ⁽⁴⁾ + biomarkers ⁽³⁾)

\$2.5B

\$3.8B

8.5%

SAM

Accessible reimbursed markets (U.S., OECD, Korea, Japan) ⁽²⁾

\$1.7B

\$2.6B

8.5%

**QT
Imaging
Penetration**

~10% SAM share by 2030

\$18M


**\$200–
250M**

—

NEW MARKET

**SaaS Biomarkers:
\$1B MARKET ⁽³⁾**

- Move to personalized, precision diagnostics
- Move to personalized treatments with therapy guidance and monitoring



If we capture as low as 10% of cash only and reimbursed segments of addressable market, we are at \$200M+ revenue scale.

(1) <https://www.futuremarketinsights.com/reports/automated-breast-ultrasound-system-market>


(2) <https://www.grandviewresearch.com/industry-analysis/breast-imaging-equipment-market> \$5.45B for 2024 with 8.9% CAGR.

(3) <https://www.archivemarketresearch.com/reports/breast-cancer-biomarkers-316622>

(4) <https://www.cdc.gov/breast-cancer/about/dense-breasts.html>


FDA Density Disclosure Requirements

Many Women Have Dense Breasts,
Which Mammograms are Inefficient
in Screening for Cancer



50% of women between the ages of 40-74 in the U.S. have dense breasts⁽¹⁾

QTscan identified abnormalities in dense breasts that were not identified by x-ray mammograms⁽²⁾



X-Ray Mammogram

QTscan

The FDA Has Recognized the
Importance of Breast Density
in Breast Cancer Screening

Mammograms Must Include Breast Density Information, New FDA Rule Says

About half of the women over the age of 40 in the U.S. have dense breast tissue, which can make cancer scans hard to read⁽³⁾



“the new rule advises physicians and patients to consider breast density alongside other cancer risk factors when deciding whether additional screening is necessary”

– Hilary Marston,
CHIEF MEDICAL OFFICER, FDA

Mammography misses 35.6–52.2% of breast cancers in dense breast tissue.⁽⁴⁾

(1) Breast Density on a Mammogram, Susan G. Komen

(2) QTI Study | Dense Breast Mass Detection

(3) “Mammograms Must Include Breast Density Information, New FDA Rule Says”, Wall Street Journal

(4) The Role of Ultrasound in Screening Dense Breasts. NCBI.

AI Adoption in Radiology and Personalized Oncology/Biomarkers

Radiology is the leading specialty for clinical AI adoption

- ~30 to 48% of radiologists report active clinical AI use; adoption continues to accelerate across imaging workflows

Most FDA-cleared clinical AI tools are in radiology

- Medical imaging remains the largest category of FDA cleared AI/ML enabled medical devices

AI is shifting from workflow support to diagnostic augmentation

- AI tools increasingly assist with detection, prioritization, quantification, and structured reporting

Cloud delivered AI is becoming the preferred deployment model

- Institutions increasingly expect centrally updated, scalable software rather than on premise installs

Oncology is moving from one-size-fits-all treatment toward biomarker-guided therapy

- Precision oncology increasingly relies on quantitative biomarkers to personalize treatment selection and monitoring

Radiomics converts imaging into quantitative biomarkers

- Imaging biomarkers can support diagnosis, prognosis, and treatment response prediction beyond visual interpretation

Breast cancer treatment increasingly requires earlier response assessment

- Imaging biomarkers are being studied for early prediction of neoadjuvant therapy response and pathologic complete response

Standardized quantitative imaging platforms are advantaged

- Reproducible, inherently quantitative modalities are better suited for robust biomarker development than subjective/operator dependent imaging

*QT Imaging is uniquely positioned at the intersection of two major healthcare shifts:
AI-enabled radiology workflows and quantitative biomarker driven precision oncology.*

Category III CPT Code Approval – X579T

- Submitted on November 3, 2025
- Approved by AMA in February 2026
- Scheduled for release on July 1, 2026, with an effective date of January 1, 2027

➤ The new **Category III code, X579T**, represents a significant milestone in the clinical and commercial advancement of QT Imaging's technology, recognizing the distinct clinical service enabled by its radiation free, compression free, 3D breast imaging platform



Breast Cancer Screening Matrix: QT Imaging Sweet Spot

Risk Category (Tyrrer-Cuzick Lifetime Risk) + Breast Density	Typical Risk Profile Description	< 40 Years	≥ 40 Years
Low Risk (<12%) (~20–30% of women)	No first-degree relatives with breast cancer No known pathogenic mutations No prior chest radiation No high-risk breast lesions Favorable reproductive/hormonal profile	No routine imaging; breast awareness	Mammography beginning at 40–45; annual or biennial
Intermediate Risk (12–19.9%) (~60–70% of women)	May have one second-degree relative Common reproductive risk factors (early menarche, late first birth, etc.) Dense Breasts No known high-risk mutation No strong clustering of early cancers	No routine imaging	Begin mammography at 40; annual or biennial depending on shared decision-making
High Risk (≥20%) (~8–12% of women)	Known pathogenic mutation (e.g., BRCA1/2) Strong family history (multiple relatives, early-onset cases) Dense Breasts Prior chest radiation before age 30 High-risk lesions (atypical hyperplasia, LCIS)	Annual breast MRI starting 25–30 Add mammogram at 30	Annual MRI + annual mammogram



QT IMAGING

Validation



Validation


- Existing FDA clearance to offer an imaging modality for all patients above 18 years old
- Received UAE regulatory approval
- NIH \$18M funding to generate a safe imaging modality for women with dense breasts
- Ongoing clinical studies at:
 - Mayo Clinic
 - Sunnybrook Cancer Center
 - To start soon: Stanford
 - In discussions: UCSF, Harvard
- Category III code, X579T

NIH has
awarded QT
Imaging about
\$18M
for new women's
imaging solution



Clinical Validation Across Screening and Oncology Applications: *Mayo Clinic – QTscan vs MRI*


- Mayo Clinic prospective feasibility study: 26 high-risk women comparing QT Imaging (QTscan) with breast MRI for supplemental screening
- Strong breast-level agreement with MRI: binary agreement between QTscan and MRI across 52 breasts
- Comparable detection profile
- All MRI-suspicious lesions were identified by QTscan



This QT Imaging Mayo Clinic pilot provides strong clinical validation and supports larger studies aimed at expanding QT Imaging adoption in high-risk and supplemental screening.

Clinical Validation Across Screening & Oncology Applications: *Sunnybrook Cancer Center – QTscan vs MRI*

- NIH/NCI-funded, to prove QT Imaging as imaging modality for early monitoring of breast cancer response to neoadjuvant chemotherapy (NAC)
- Major oncology need:
 - treatment response that can be **performed in days to weeks rather than months**, supporting more adaptive and personalized therapy decisions
- Lesion volume agreement across QTscan and MRI images: strong correlation observed as published in *Tomography Journal*
- Ongoing 100-patient study to compare advanced quantitative ultrasound findings with treatment response



This Sunnybrook/QT Imaging program extends utility of QTscan beyond diagnostic imaging into treatment-response monitoring, expanding its potential role across the breast cancer care pathway.

Regulatory Activities Additional to FDA Clearance

Saudi FDA (SFDA)



Submit Dossier —Feb, 2026
Authorized Rep via Gulf Medical;
MDS-GS-004

Under SFDA
Regulatory Review

Expected Marketing
Authorization
Target: Q2 2026

UAE MOHAP



Dossier Preparation
Leverage SFDA submission;
MOHAP registration

UAE Submission
MOHAP device
registration

Approval early!
Q1 2026

CE Mark (EU MDR)



Notified Body Engagement
BSI/Alternate;
plan conformity route

Submit Technical
Documentation
CER, Annex II/III,
PMS/PMCF

Expected CE Mark
Target: Q4 2026



QT IMAGING

Business Model,
Partnerships &
Financial Trajectory



Business Model

HW+ SaaS +AI Diagnostic Layer



intelerad



Radiology

Referring MD



Cloud SaaS Platform

Business Model:

- Hardware sale (scanner): upfront revenue
- SaaS platform: recurring revenue
- AI diagnostic layer: higher margin

**Hardware gets us in the door.
Software builds the company.**

Business Partnerships Today



Under Distribution Agreement with NXC Imaging (Subsidiary of Canon Medical Systems) for U.S. market



Under Contract Manufacturing Agreement with Canon Medical Systems



شركة الخليج الطبية المحدودة
GULF MEDICAL CO. LTD.

Under Distribution Agreement with Gulf Medical for Kingdom of Saudi Arabia (KSA) market



شركة الناهي الطبية
AL NAGHI MEDICAL

Under Distribution Agreement with Al Naghi Medical for the United Arab Emirates Territory

Business Partnerships

U.S. and International Expansion



- Under Distribution Agreement with NXC Imaging (Subsidiary of Canon Medical Systems) for U.S.A. market
 - Four additional distributors signed by NXC Imaging to cover sales across all states
 - Committed quarterly minimum order quantities (MOQs) for scanner shipments till end of 2026

2025	Q1	Q2	Q3	Q4	
	6	10	12	12	40

2026	Q1	Q2	Q3	Q4	
	13	15	15	17	60



- Under Distribution Agreement with Gulf Medical for KSA market
 - Committed MOQs for scanner shipments through 2028

2026	Q1	Q2	Q3	Q4	
	5	5	5	5	20

2027	Q1	Q2	Q3	Q4	
	8	8	8	8	32

2028	Q1	Q2	Q3	Q4	
	10	10	10	10	40






- Under Distribution Agreement with Al Naghi Medical for the United Arab Emirates Territory
 - Committed MOQs for scanner shipments through 2028

2026	Q1	Q2	Q3	Q4	
	1	2	2	2	7

2027	Q1	Q2	Q3	Q4	
	4	4	4	4	16

2028	Q1	Q2	Q3	Q4	
	5	5	5	5	20


QTI Precision Pathway – Cloud SaaS Platform

	Core	Operational	Advanced	Enterprise
	System software updates	Collaboration & data sharing	Quantitated biomarkers	Multiuser access
	Long term technology relevance		Automated analysis	Enterprise collaboration
			Precision reporting	
 Biomarker / Analysis			✓	✓
 QTI Precision Share		✓	✓	✓
 Scanner Evergreen	✓	✓	✓	✓


Platform upside – AI/Biomarkers, additional reimbursement codes

Financial Trajectory

Yearly Revenue and Scanner Shipments




Quarterly Revenue and Scanner Shipments



FY-2024A **FY-2025A** **FY-2026A** **CAGR 24'A - 26'E**

Revenue (\$k)	\$4,879	\$18,926	\$39,000	
Growth %		287.90%	106.10%	182.70%
Shipments	12	40	80	


Financial Trajectory



QT Imaging is scaling a commercial business.

Competitive Sales Cycle and Clinical Sites Adoption Curve


Segment/ Sales Cycle	Existing Imaging Equipment	QT Imaging Equipment
Hospital	12 to 18 months	6 to 8 months
Outpatient Imaging	6 to 12 months	4 to 6 months
Functional Medicine (cash pay)		6 to 8 months



QT Imaging's differentiated value proposition enables adoption timelines competitive with incumbent imaging technologies.



Planned Evolution to Hybrid Commercial Model as Scale Increases



Commercial strategy balances capital efficiency today with increasing control and margin expansion over time.

QT Imaging Is Executing on Its Early Commercial Scale With Multiple Near Term Value Inflection Points

- FDA cleared, clinically validated technology addressing a **large unmet need in dense breast imaging** – this is a **category-defining company** at the exact moment the market is ready
- Commercial infrastructure **established** through **manufacturing, distribution, and international expansion partnerships**
- Revenue and scanner shipment growth and consistent execution demonstrate **transition from development stage to commercial scale**
- **Category III CPT code** creates pathway toward reimbursement and broader adoption
- Proprietary quantitative imaging platform enables **long term expansion into AI driven diagnostics and imaging biomarkers** – scalable model



***Building the future of breast imaging
from an already commercialized platform.***



QT IMAGING

Thank You!

